+Compare
ACST
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
13.97M

ACST Acasti Pharma Forecast, Technical & Fundamental Analysis

a manufacturer of Pharmaceutical products

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ACST with price predictions
08:00 PM EDT Sep 20, 2023

ACST in -4.78% downward trend, sliding for three consecutive days on September 21, 2023

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ACST declined for three days, in of 377 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 12, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on ACST as a result. In of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Aroon Indicator for ACST entered a downward trend on September 21, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for ACST just turned positive on August 30, 2023. Looking at past instances where ACST's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACST advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .

ACST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.218) is normal, around the industry mean (22.643). P/E Ratio (0.000) is within average values for comparable stocks, (131.410). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.929). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (196.078) is also within normal values, averaging (308.526).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ACST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 402 to 410.6B. NVO holds the highest valuation in this group at 410.6B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was 32%, and the average quarterly price growth was 32%. SKYED experienced the highest price growth at 81%, while SEEL experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was 31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

ACST is expected to report earnings to fall 79.63% to -10 cents per share on November 13

Acasti Pharma ACST Stock Earnings Reports
Q3'23
Est.
$-0.11
Q2'23
Missed
by $0.42
Q1'23
Missed
by $0.51
Q4'22
Beat
by $0.03
Q1'22
Beat
by $0.04
The last earnings report on August 11 showed earnings per share of -54 cents, missing the estimate of -11 cents. With 30.57K shares outstanding, the current market capitalization sits at 13.97M.
A.I. Advisor
published General Information

General Information

a manufacturer of Pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
3009 Boulevard de la Concorde East
Phone
+1 450 686-4555
Employees
7
Web
https://www.acastipharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WAVE2.450.14
+6.06%
Eco Wave Power Global AB (publ)
RTO36.62-0.16
-0.44%
Rentokil Initial plc
HMY4.29-0.07
-1.61%
Harmony Gold Mining Company Limited
BALY14.66-0.28
-1.87%
Bally's Corp
ORTX6.97-0.18
-2.45%
Orchard Therapeutics plc

ACST and

Correlation & Price change

A.I.dvisor tells us that ACST and MBIO have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACST and MBIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACST
1D Price
Change %
ACST100%
-5.64%
MBIO - ACST
32%
Poorly correlated
-4.94%
SCNI - ACST
31%
Poorly correlated
-1.61%
ATAI - ACST
30%
Poorly correlated
N/A
ATOS - ACST
30%
Poorly correlated
+5.06%
AVRO - ACST
29%
Poorly correlated
-0.65%
More

Groups containing ACST

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACST
1D Price
Change %
ACST100%
-5.64%
pharmaceuticals
(undefined stocks)
13%
Poorly correlated
-0.53%
north america
(undefined stocks)
8%
Poorly correlated
-0.27%